Gene Therapy

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

Insights from a genome-wide association study identify novel genetic loci

Telomir-1 shows promising results in restoring vision and retinal structure in age-related macular degeneration, marking a significant advancement in treatment.

At the Retina World Congress, we spoke with Siegfried Priglinger, MD, about ensuring the best outcomes for preschool-aged patients

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

Insights from a genome-wide association study identify novel genetic loci

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there currently are no approved treatments.

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

A large-scale study indicates women are more likely to develop the inherited corneal condition

ENCELTO is the first and only FDA-approved treatment for MacTel.

Neurologist warns about recurrent optic neuritis attacks.

ENCELTO is the first and only FDA-approved treatment for MacTel.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease